N17350 for Cancer

(OP-NEU-101 Trial)

This trial aims to determine if the new treatment, N17350 (an experimental treatment), can shrink or halt the growth of advanced solid tumors, assess its safety, and identify the optimal dose. Participants will receive injections directly into their tumors and attend regular checkups and scans to monitor progress. Suitable candidates for this trial include individuals with advanced solid tumors that have not responded well to other treatments and have tumors accessible for injection. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial protocol does not specify if you must stop taking your current medications. However, you cannot participate if you have taken certain anticancer therapies or systemic medications like anticoagulants and corticosteroids shortly before the trial starts.

Research has shown that N17350, a new cancer treatment, has promising safety results from early studies. These studies found that N17350 effectively attacks and kills cancer cells while sparing healthy immune cells. This suggests it might combat tumors without significantly impacting the body's immune system. In early trials with patients, researchers monitored side effects and safety, a standard practice for new treatments. Although these results are preliminary, they suggest the treatment is generally well-tolerated. However, as with any new treatment, some side effects may occur, and ongoing studies aim to better understand these and determine the safest dose for future use.¹²³⁴⁵

Researchers are excited about N17350 because it offers a new approach to treating cancer, specifically through direct intratumoral injections. Unlike traditional systemic therapies like chemotherapy or immunotherapy, which affect the whole body, N17350 is injected directly into the tumor. This targeted delivery method could potentially reduce side effects and improve effectiveness by concentrating the treatment where it's needed most. Additionally, the study explores various doses and lesion types, which may provide insights into optimal treatment strategies for different cancer forms.

Research has shown that N17350 may help treat advanced solid tumors. In this trial, participants will receive N17350 as an intratumoral injection, with different arms studying various dosages and types of lesions, including superficial and visceral lesions. A single dose of N17350 shrank both primary tumors and metastases. It also enhanced the effectiveness of other cancer treatments. N17350 successfully killed cancer cells from various sources, including new and recurrent ovarian tumors. By direct injection into tumors, it aids the immune system in fighting cancer. Early studies consistently demonstrated N17350's effectiveness across different cancer types. These findings suggest that N17350 could effectively reduce or halt tumor growth in advanced solid tumors.¹²³⁶⁷